Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
SYNTOCINON is a synthetic oxytocin injection approved in 1980 for postpartum hemorrhage and female sexual dysfunction. It acts on uterine smooth muscle to stimulate contractions by increasing intracellular calcium, with response dependent on uterine sensitivity and oxytocin receptor concentration. The drug is administered via injection and is indicated primarily for obstetric emergencies and select gynecological conditions.
As LOE approaches, the brand team will likely shift focus toward life-cycle extensions, line extensions, or portfolio transitions, with smaller teams and declining resource allocation expected.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SYNTOCINON offers stable but declining career prospects as the product approaches loss of exclusivity. Roles focus on defending market share against generics and exploring niche segments like female sexual dysfunction rather than growth or innovation.
Worked on SYNTOCINON at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.